Novo VP Weighs In on Approval of Lilly’s Obesity Pill

Summary

• Jamey Millar emphasizes Novo Nordisk's pioneering role in the weight-loss drug category, launching Wegovy injectable in 2021 and the oral pill form first.
• Wegovy pill shows 17% weight loss efficacy, comparable to injectable, with strong tolerability—only 2% of patients discontinue due to adverse events.
• Demand for the oral pill is strong, with unprecedented volume and receptivity, attracting new prescribers and patients, many not previously on GLP-1 drugs.
• Novo focuses on user adoption and adherence, highlighting a subscription model for the injectable form that offers savings up to $1200 per year to encourage long-term use.
• Eli Lilly's newly approved obesity pill is priced at $149 per month for cash payers, matching Novo's pricing; Millar frames this as imitation and flattery.
• The subscription model is unique in the industry, initially rolled out through partners like Ro, WeightWatchers, and LifeMD, with plans to expand to Hims & Hers, Sesame, and Novo Care pharmacy.
• The weight-loss drug market is consumer-centric, with consumers acting as end users, decision makers, and budget holders, unlike traditional pharmaceutical markets.
• Novo's strategy centers on efficacy, tolerability, and affordability through dynamic pricing and telehealth partnerships to sustain momentum despite competition.